113333-60-1Relevant academic research and scientific papers
NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY
-
Page/Page column 69; 73-74, (2011/05/05)
The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particuarl embodiments, the compositions target DXR. In specific embodiments, the compositions are electron-deficient heterocyclic rings.
Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase
Deng, Lisheng,Sundriyal, Sandeep,Rubio, Valentina,Shi, Zheng-Zheng,Song, Yongcheng
supporting information; experimental part, p. 6539 - 6542 (2010/04/04)
1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) in the non-mevalonate pathway found in most bacteria is a validated anti-infective drug target. Fosmidomycin, a potent DXR inhibitor, is active against Gram-negative bacteria. A coordination chemistry and structure based approach was used to discover a novel, lipophilic DXR inhibitor with an IC50 of 1.4 μM. It exhibited a broad spectrum of activity against Gram-negative and -positive bacteria with minimal inhibition concentrations of 20-100 μM (or 3.7-19 μg/mL).
Synthesis of Masked Glyoxal Monoxime and 1-Hydroxylaminoacetaldehyde Derivatives
Gehrer, Eugen,Kloetzer, Wilhelm,Singewald, Nicolas,Stadlwieser, Josef
, p. 633 - 635 (2007/10/02)
Sodium ethoxide-catalyzed cleavage of azo-N,N'-bis(2,2-diethoxyethyl)-N,N'-dioxide (2) to an E/Z mixture (6.5:1) of 1-hydroxyimino-2,2-diethoxyethane (3a) is reported.Alkylation of the oxime sodium salt provides mainly the E-isomers of the alkyloxyimino-2
